Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Jul;38(1):45–51. doi: 10.1111/j.1365-2125.1994.tb04320.x

Indomethacin and cognitive function in healthy elderly volunteers.

P N Bruce-Jones 1, P Crome 1, L Kalra 1
PMCID: PMC1364836  PMID: 7946936

Abstract

1. Cognitive function was studied after single and multiple doses of indomethacin (I) and matched placebo (P) in 20 healthy elderly volunteers using a double-blind crossover design. 2. Arousal, attention, integration, coordination, memory and mood were investigated using a battery of psychomotor tests and the Hospital Anxiety and Depression Scale. Assessments were performed before and after the first and last doses of a 7 day course of medication. 3. Critical flicker fusion threshold fell by a mean of 1.96% on indomethacin compared with a 1.13% rise on placebo 5 h after the first dose (P = 0.029). A beneficial effect on choice reaction time latency (P = 0.012) was seen both after acute and continuing administration of indomethacin. Performance at the most discriminating level (level 3) of the paired word association test was significantly better following 8 days of treatment with indomethacin in the younger (55-65 year-old) age group (P = 0.001). 4. There was no significant difference in performance on the symbol-digit substitution test and the continuous attention task. No change was seen in hospital anxiety and depression scale scores. 5. These results suggest that performance on tests of sensorimotor coordination and short term memory may improve in healthy volunteers following indomethacin administration, whereas tests of attention and psychomotor speed remain unaffected. However, further controlled studies in rheumatic patients are needed to evaluate fully the psychomotor effects of indomethacin and other NSAIDs in clinical practice.

Full text

PDF
45

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ames F. R. Cognitive dysfunction caused by non-steroidal anti-inflammatory drugs. S Afr Med J. 1983 Jul 2;64(1):5–5. [PubMed] [Google Scholar]
  2. Carless J. E., Rowe J. S. The use of Critical Flicker Fusion frequency test for evaluating some central nervous effects of two indomethacin formulations. J Pharm Pharmacol. 1981 May;33(5):336–337. doi: 10.1111/j.2042-7158.1981.tb13797.x. [DOI] [PubMed] [Google Scholar]
  3. Fink M., Irwin P. Central nervous system effects of aspirin. Clin Pharmacol Ther. 1982 Sep;32(3):362–365. doi: 10.1038/clpt.1982.172. [DOI] [PubMed] [Google Scholar]
  4. Goodwin J. S., Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum. 1982 Aug;25(8):1013–1015. doi: 10.1002/art.1780250817. [DOI] [PubMed] [Google Scholar]
  5. Hindmarch I. A 1,4-benzodiazepine, temazepam (K 3917), its effect on some psychological parameters of sleep and behaviour. Arzneimittelforschung. 1975 Nov;25(11):1836–1839. [PubMed] [Google Scholar]
  6. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol. 1980 Sep;10(3):189–209. doi: 10.1111/j.1365-2125.1980.tb01745.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. ISAACS B., WALKEY F. A. A SIMPLIFIED PAIRED-ASSOCIATE TEST FOR ELDERLY HOSPITAL PATIENTS. Br J Psychiatry. 1964 Jan;110:80–83. doi: 10.1192/bjp.110.464.80. [DOI] [PubMed] [Google Scholar]
  8. Johnson A. G., Day R. O. The problems and pitfalls of NSAID therapy in the elderly (Part I). Drugs Aging. 1991 Mar;1(2):130–143. doi: 10.2165/00002512-199101020-00005. [DOI] [PubMed] [Google Scholar]
  9. Keesey U. T. Variables determining flicker sensitivity in small fields. J Opt Soc Am. 1970 Mar;60(3):390–398. doi: 10.1364/josa.60.000390. [DOI] [PubMed] [Google Scholar]
  10. Leigh T. J., Bird H. A., Hindmarch I., Wright V. The evaluation of a nonsteroidal anti-inflammatory drug (tenoxicam) in the treatment of sleep disturbance in osteoarthritic patients. Clin Rheumatol. 1989 Dec;8(4):489–493. doi: 10.1007/BF02032101. [DOI] [PubMed] [Google Scholar]
  11. Minocha A., Barth J. T., Herold D. A., Gideon D. A., Spyker D. A. Modulation of ethanol-induced central nervous system depression by ibuprofen. Clin Pharmacol Ther. 1986 Feb;39(2):123–127. doi: 10.1038/clpt.1986.22. [DOI] [PubMed] [Google Scholar]
  12. Nuotto E., Saarialho-Kere U. Actions and interactions of indomethacin and diazepam on performance in healthy volunteers. Pharmacol Toxicol. 1988 May;62(5):293–297. doi: 10.1111/j.1600-0773.1988.tb01890.x. [DOI] [PubMed] [Google Scholar]
  13. O'Brien W. M., Bagby G. F. Rare adverse reactions to nonsteroidal antiinflammatory drugs. 4. J Rheumatol. 1985 Aug;12(4):785–790. [PubMed] [Google Scholar]
  14. Pigache R. M. Comparison of scoring methods for tests of attention, including an error index for use with schizophrenic patients. Percept Mot Skills. 1976 Feb;42(1):243–253. doi: 10.2466/pms.1976.42.1.243. [DOI] [PubMed] [Google Scholar]
  15. Pullar T., Myall O., Haigh J. R., Lowe J. R., Dixon J. S., Bird H. A. The effect of indomethacin on the psychomotor function of patients with rheumatic diseases. Br J Rheumatol. 1988 Jun;27(3):227–229. doi: 10.1093/rheumatology/27.3.227. [DOI] [PubMed] [Google Scholar]
  16. Saarialho-Kere U., Julkunen H., Mattila M. J., Seppälä T. Psychomotor performance of patients with rheumatoid arthritis: cross-over comparison of dextropropoxyphene, dextropropoxyphene plus amitriptyline, indomethacin, and placebo. Pharmacol Toxicol. 1988 Oct;63(4):286–292. doi: 10.1111/j.1600-0773.1988.tb00956.x. [DOI] [PubMed] [Google Scholar]
  17. Seideman P., von Arbin M. Cerebral blood flow and indomethacin drug levels in subjects with and without central nervous side effects. Br J Clin Pharmacol. 1991 Apr;31(4):429–432. doi: 10.1111/j.1365-2125.1991.tb05558.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Tiplady B. A continuous attention test for the assessment of the acute behavioral effects of drugs. Psychopharmacol Bull. 1988;24(2):213–216. [PubMed] [Google Scholar]
  19. Turner P. Critical flicker frequency and centrally-acting drugs. Br J Ophthalmol. 1968 Mar;52(3):245–250. doi: 10.1136/bjo.52.3.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wysenbeek A. J., Klein Z., Nakar S., Mane R. Assessment of cognitive function in elderly patients treated with naproxen. A prospective study. Clin Exp Rheumatol. 1988 Oct-Dec;6(4):399–400. [PubMed] [Google Scholar]
  21. Zigmond A. S., Snaith R. P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES